Clinical Policy: Tobramycin (Bethkis, Kitabis Pak, TOBI, TOBI Podhaler)

Reference Number: CP.PHAR.211
Effective Date: 05.01.16
Last Review Date: 02.21
Line of Business: Commercial, HIM*, Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Tobramycin (Bethkis®, Kitabis™ Pak, TOBI®, TOBI® Podhaler™) is an aminoglycoside antibacterial drug.

*For Health Insurance Marketplace (HIM), Bethkis, brand Kitabis Pak, brand TOBI, and TOBI Podhaler are non-formulary and cannot be approved using these criteria; refer to the formulary exception policy, HIM.PA.103.

FDA Approved Indication(s)
Bethkis, Kitabis Pak, TOBI, and TOBI Podhaler are indicated for the management of cystic fibrosis (CF) in patients with Pseudomonas aeruginosa. Kitabis Pak and TOBI are specifically indicated for patients 6 years of age and older.

Limitation(s) of use: Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in one second (FEV₁) < 25% or > 75% predicted (< 40% or > 80% predicted for Bethkis), or patients colonized with Burkholderia cepacia.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Bethkis, Kitabis Pak, TOBI, and TOBI Podhaler are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Cystic Fibrosis (must meet all):
      1. Diagnosis of CF;
      2. Prescribed by or in consultation with a pulmonologist, an infection disease specialist, or an expert in treatment of cystic fibrosis;
      3. Age ≥ 6 years;
      4. Pseudomonas aeruginosa is present in at least one airway culture;
      5. If tobramycin is prescribed concurrently (or for alternating use) with Cayston®, documentation supports inadequate response to either agent alone (e.g., deteriorating pulmonary status, recurrent pulmonary exacerbations);
      6. Dose does not exceed one of the following (a or b):
         a. Inhalation solution (Bethkis, Kitabis Pak, TOBI): 600 mg per day administered on a 28 days on/28 days off cycle;
         b. Inhalation powder (TOBI Podhaler): 224 mg per day administered on a 28 days on/28 days off cycle.
**Clinical Policy**

Tobramycin

**Approval duration:**

- **Medicaid** – 6 months
- **HIM** – 6 months for tobramycin nebulized solution (*refer to HIM.PA.103 for Bethkis, brand Kitabis Pak, brand TOBI, and TOBI Podhaler*)
- **Commercial** – Length of Benefit

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Cystic Fibrosis** (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by reduction in respiratory symptoms (e.g., cough, wheezing, sputum production, or pulmonary exacerbations due to Pseudomonas aeruginosa);
3. If tobramycin is prescribed concurrently (or for alternating use) with Cayston, documentation supports inadequate response to either agent alone (e.g., deteriorating pulmonary status, recurrent pulmonary exacerbations);
4. If request is for a dose increase, new dose does not exceed one of the following (a or b):
   a. Inhalation solution (Bethkis, Kitabis Pak, TOBI): 600 mg per day administered on a 28 days on/28 days off cycle;
   b. Inhalation powder (TOBI Podhaler): 224 mg per day administered on a 28 days on/28 days off cycle.

**Approval duration:**

- **Medicaid** – 12 months
- **HIM** – 12 months for tobramycin nebulized solution (*refer to HIM.PA.103 for Bethkis, brand Kitabis Pak, brand TOBI, and TOBI Podhaler*)
- **Commercial** – Length of Benefit

**B. Other diagnoses/indications** (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   **Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.
III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
CF: cystic fibrosis
FDA: Food and Drug Administration
FEV₁: forced expiratory volume in one second

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
• Contraindication(s): known hypersensitivity to any aminoglycoside
• Boxed warning(s): none reported

Appendix D: General Information
• Tobramycin is recommended for chronic use in both mild and moderate-to-severe disease per the American Thoracic Society 2013 CF guidelines. Severity of lung disease is defined by FEV₁ predicted as follows: normal, > 90% predicted; mildly impaired, 70-89% predicted; moderately impaired, 40-69% predicted; and severely impaired, < 40% predicted.
• The use of continuous alternating therapy (i.e., alternating different inhaled antibiotics in order to provide continuous therapy) lacks sufficient evidence. The efficacy of this practice was evaluated in a randomized, double-blind, phase 3 trial. 90 patients received 28-days inhaled tobramycin alternating with either 28-days inhaled aztreonam or placebo. Although the study found reduced exacerbation and respiratory hospitalization rates with the alternating tobramycin/aztreonam regimen compared to tobramycin/placebo, it was underpowered, and these results were not statistically significant.
• CF Foundation per American Thoracic Society 2014 CF guidelines strongly recommends inhaled tobramycin (300 mg twice daily) for 28 days for treatment of initial or new growth of *P. aeruginosa* from an airway culture.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobramycin inhalation solution (Bethkis, Kitabis Pak, TOBI)</td>
<td>300 mg inhaled BID for 28 days (followed by 28 days off tobramycin therapy)</td>
<td>600 mg/day</td>
</tr>
<tr>
<td>Tobramycin inhalation powder (TOBI Podhaler)</td>
<td>112 mg (4 capsules) inhaled BID for 28 days (followed by 28 days off tobramycin therapy)</td>
<td>224 mg/day</td>
</tr>
</tbody>
</table>
VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobramycin inhalation solution (Bethkis)</td>
<td>4 mL single-dose ampule: 300 mg</td>
</tr>
<tr>
<td>Tobramycin inhalation solution (Kitabis Pak)</td>
<td>5 mL single-dose ampule: 300 mg</td>
</tr>
<tr>
<td></td>
<td>Co-packaged with a PARI LC PLUS Reusable Nebulizer</td>
</tr>
<tr>
<td>Tobramycin inhalation solution (TOBI)</td>
<td>5 mL single-dose ampule: 300 mg</td>
</tr>
<tr>
<td>Tobramycin inhalation powder (TOBI Podhaler)</td>
<td>Capsule: 28 mg</td>
</tr>
</tbody>
</table>

VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7682</td>
<td>Tobramycin, inhalation solution, FDA-approved final product, noncompounded,</td>
</tr>
<tr>
<td></td>
<td>unit dose form, administered through DME, per 300 mg</td>
</tr>
<tr>
<td>J7685</td>
<td>Tobramycin, inhalation solution, compounded product, administered through</td>
</tr>
<tr>
<td></td>
<td>DME, unit dose form, per 300 mg</td>
</tr>
</tbody>
</table>
Tobramycin

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bethkis added (limited distribution – see references for distribution network). Kitabis authorized generic added. FEV1 delineation of ≤90% added to initial criteria. Allergy contraindication removed. Efficacy statement edited to indicate a general positive response to therapy.</td>
<td>05.17</td>
<td>05.17</td>
</tr>
</tbody>
</table>
| 1Q18 annual review:  
- Policies combined for Centene Medicaid and Commercial lines of business.  
- Medicaid: Removed baseline FEV requirement.  
- Commercial: Added initial requirement for no concurrent/alternating use with aztreonam.  
- Both: Added allowance for concurrent/alternating use with aztreonam pending supportive documentation of inadequate response to either agent alone.  
- Added Appendix C: General Information  
- References reviewed and updated | 10.27.17 | 02.18 |
| 1Q 2019 annual review: added HIM; no significant changes; references reviewed and updated. | 10.17.18 | 02.19 |
| 1Q 2020 annual review: no significant changes; clarified brand TOBI and Kitabis Pak are non-formulary, but policy does apply to generic tobramycin nebulized solution; references reviewed and updated. | 10.28.19 | 02.20 |
| 1Q 2021 annual review: added prescriber restrictions of pulmonologist, infection disease specialist, or expert in treatment of cystic fibrosis; added positive response to therapy examples: reduction in respiratory symptoms (e.g., cough, wheezing, sputum production, or pulmonary exacerbations due to Pseudomonas aeruginosa) in continuation criteria; updated Appendix D; references reviewed and updated. | 01.07.21 | 02.21 |

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.
The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or
remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.